Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Diabetes Technol Ther ; 22(12): 943-947, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32324061

RESUMO

Background: The aim of this study was to determine the performance of the Dexcom G6 continuous glucose monitoring (CGM) system across three sensor wear sites in pregnant women with diabetes in the second or third trimesters. Methods: Participants with type 1 (T1D), type 2 (T2D), or gestational (GDM) diabetes mellitus were enrolled at three sites. Each wore two G6 sensors on the abdomen, upper buttock, and/or posterior upper arm for 10 days and underwent a 6-h clinic session between days 3 and 7 of sensor wear, during which YSI reference blood glucose values were obtained every 30 min. No intentional glucose manipulations were performed. Accuracy metrics included the proportion of CGM values that were within ±20% of paired reference values >100 mg/dL or ±20 mg/dL of YSI values ≤100 mg/dL (hereafter referred to as %20/20), as well as the analogous %15/15, %30/30, and %40/40. The mean absolute relative difference (MARD) between CGM-YSI pairs was also calculated. Results: Thirty-two participants with T1D (n = 20), T2D (n = 3), or GDM (n = 9) were enrolled: 19 were in the second trimester and 13 were in the third trimester of pregnancy. Compared with the reference, 92.5% of CGM values were within ±20%/20 mg/dL. The overall MARD and that of sensors worn on the abdomen, upper buttock, and posterior upper arm was 10.3%, 11.5%, 11.2%, and 8.7%, respectively. There were no device-related adverse events. Skin reactions at the insertion sites were absent or minor. Conclusions: The Dexcom G6 CGM system is accurate and safe in pregnant women with diabetes.


Assuntos
Automonitorização da Glicemia , Glicemia , Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Adulto , Glicemia/análise , Automonitorização da Glicemia/normas , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/tratamento farmacológico , Feminino , Humanos , Gravidez , Gravidez em Diabéticas , Gestantes , Reprodutibilidade dos Testes
2.
Diabetes Technol Ther ; 22(7): 538-540, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32031415

RESUMO

Eversense is a long-term implantable continuous glucose monitoring (CGM) system. Difficulty in locating and removing implanted sensors is one of the issues limiting its use. We propose using near-infrared (NIR) light to locate implanted glucose sensors. NIR light was used to locate implanted glucose sensors in 30 patients (age 18-62 years) with type 1 diabetes who use Eversense sensors for CGM. Duration of sensor implantation was 10-40 weeks (median 12 weeks). Out of 30 patients with type 1 diabetes, the NIR light located the implanted sensor in 24 patients (success rate 80%) within 5 s. Sensor implantation at the skin with tattoos and excessive freckles were two main reasons for failure to locate sensors using NIR. We report an innovative method to locate implanted glucose sensors in seconds, which would reduce the time significantly to remove the sensor.


Assuntos
Técnicas Biossensoriais , Automonitorização da Glicemia/instrumentação , Remoção de Dispositivo/métodos , Diabetes Mellitus Tipo 1 , Próteses e Implantes , Adolescente , Adulto , Glicemia , Diabetes Mellitus Tipo 1/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Adulto Jovem
5.
Diabetes Obes Metab ; 22(4): 583-589, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31789447

RESUMO

AIM: To compare glycaemic metrics at 3 and 6 months in patients with type 1 diabetes on a 670G hybrid closed-loop (HCL) system after using a sensor-augmented pump (SAP) for at least 3 months. MATERIALS AND METHODS: A retrospective study from a centre that has the largest number of 670G users in the United States was conducted. Data from 202 SAP users were reviewed. Sixty-one patients were excluded (two for steroid use, four for pregnancy, 27 for previous Enlite use, and 28 for non-continuous use of 670G). Out of 141 patients who met the inclusion criteria, 127 (aged 21-68 years) had complete data. RESULTS: HbA1c levels decreased by 0.4% at 3 months and were maintained at 6 months (7.6 ± 0.07 vs. 7.2 ± 0.08, P < 0.001) with no weight gain at 6 months. Time-in-range (70-180 mg/dL) increased from 59.5% ± 1.1% to 70.2% ± 1.2% and 70.1% ± 1.1% at 3 and 6 months (P < 0.001), respectively. At 6 months, time spent in hypoglycaemia (<70 mg/dL) and time spent in hyperglycaemia (>180 mg/dL) were reduced by 30% (2.2% ± 0.2% vs. 3.2% ± 0.2%; P < 0.05) and 26% (28.3% ± 1.2% vs. 38.1% ± 1.2%; P < 0.001), respectively. More time in auto-mode was associated with improved continuous glucose monitoring metrics, lower HbA1c and decreased glycaemic variability. Time in auto-mode declined in men after 3 months, while women maintained similar auto-mode use throughout the study. CONCLUSIONS: The HCL system improved HbA1c levels and time-in-range, and decreased time spent in hypoglycaemia and hyperglycaemia at 6 months. Auto-mode use was significantly correlated with continuous glucose monitoring metrics and glycaemic outcomes.


Assuntos
Diabetes Mellitus Tipo 1 , Glicemia , Automonitorização da Glicemia , Diabetes Mellitus Tipo 1/tratamento farmacológico , Feminino , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Sistemas de Infusão de Insulina , Masculino , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...